What is Bausch + Lomb's gross profit margin?

What is Bausch + Lomb's latest dividend and current dividend yield?

What factors drove the changes in Bausch + Lomb's revenue and profit?

What were the key takeaways from Bausch + Lomb's earnings call?

What does Bausch + Lomb do and what are its main business segments?

What is the market's earnings forecast for Bausch + Lomb next quarter?

What guidance did Bausch + Lomb's management provide for the next earnings period?

Did Bausch + Lomb beat or miss consensus estimates last quarter?

- **Record Q4 Performance**: $1.4B revenue, 23.5% EBITDA margin, Miebo up 111% YoY.
- **2026 Growth Targets**: 5-7% revenue growth, 15% EBITDA expansion, 19% margin target.
- **Pipeline Success**: AREDS3 launch, Blink Triple Care preservative-free, and contact lens material Phase 1 data positive.
- **Financial Discipline**: 42% cash flow conversion in 2025, CapEx reduction to 5-6% of revenue.

**【CEO Summary Section】**
- Q4 2025 revenue reached $1.4 billion, the highest in company history, with 7% constant currency growth. Adjusted EBITDA margin hit 23.5%, up 330 basis points year-over-year.
- Miebo revenue grew 111% YoY to $112 million in Q4, driving Pharma segment growth. Xiidra revenue was $95 million, tracking in line with expectations.
- Surgical segment recovery post-enVista recall: Implantables grew 5%, Premium IOLs up 20% YoY. Contact Lens business outperformed market with 8% Q4 growth, China up 7%.
- 2026 guidance: Revenue $5.375B-$5.475B (5-7% growth), adjusted EBITDA $1B-$1.05B (15% growth). Focus on margin expansion, R&D investment (7.5-8% of revenue), and free cash flow improvement.

**【CFO Financial Commentary】**
- Full-year 2025 revenue $5.101 billion (+5%), adjusted EBITDA $891 million (+15%). Q4 adjusted EBITDA $330 million, margin 23.5%.
- Segment performance: Vision Care (+6%), Surgical (+4 ex-recall), Pharma (+6). Gross margin 61% for the year, tariffs impacting 80bps in Q4.
- 2026 financial targets: 19% EBITDA margin (vs 17.5% in 2025), 45% cash flow conversion, CapEx $285 million.

**【Q&A Highlights】**
- **Miebo Growth**: Peak sales estimate raised to $600+ million, driven by 113% YoY prescription growth. Investment stability allows profit margin expansion.
- **Competitive Dynamics**: Contact Lens outperformed market (+8% Q4 vs +4% industry). Surgical segment resilient despite recall, Implantables +5% Q4.
- **Margin Expansion**: 2026 EBITDA margin target 19% via SG&A leverage, gross margin improvement (62% target), and R&D efficiency.
- **Pipeline Momentum**: AREDS3 launch, preservative-free Blink Triple Care, and next-gen contact lens material in Phase 1 trials.
- **Free Cash Flow**: 2025 conversion 42%, targeting 45% in 2026 with CapEx step-down to 5-6% of revenue.

Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript

- **Revenue Beat**: Q3 revenue $1.281B (+6% YoY), driven by 71% YoY Miebo growth and 27% premium IOLs. Adjusted EBITDA margin 19% (+400bps QoQ).
- **Financial Excellence**: 4th strategic pillar focuses on cost control, with SG&A as % of revenue down 290bps QoQ. Free cash flow $87M, 66% EBITDA conversion.
- **Pipeline Momentum**: EnVista IOLs at 82% pre-recall levels; Bioactive lens and glaucoma med in pipeline. Surgical segment recovery faster than expected.
- **Market Expansion**: Dry eye TRx +110% YoY; LUMIFY YTD +13%. China Singles' Day results to guide 2026 contact lens strategy.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 revenue of $1.281 billion (+6% YoY) driven by 6% growth in Vision Care, 7% in Pharma, and 27% in premium IOLs. Miebo revenue reached $84 million (+71% YoY), Xiidra at $87 million, and contact lens portfolio up 6%.
- **Strategic Pillars**: Introduced 'financial excellence' as 4th pillar, focusing on disciplined cost management, margin expansion, and cash flow optimization. Q3 adjusted EBITDA margin improved 400bps to 19%.
- **Pipeline Momentum**: EnVista IOL sales at 82% of pre-recall levels, Envy at 91%, with September sales surpassing Q1 2025. Surgical segment revenue $215 million (+1% YoY). Consumer brands like LUMIFY (+13% YTD) and Blink (+37%) showed strong growth.

**【CFO Financial Commentary】**
- **Financial Highlights**: Adjusted EBITDA $243 million (+7% YoY), free cash flow $87 million. Maintained 2025 revenue guidance ($5.05-5.15B) with updated EBITDA range ($870-910M). Gross margin 61.7% (-130bps YoY) due to product mix and recall impact. R&D investment $95 million (+13% YoY).
- **Tariff Management**: Expect to offset 2025 tariff impact; 2026 outlook dependent on policy developments. Free cash flow conversion 66% in Q3.

**【Q&A Key Highlights】**
- **Contact Lens Market**: Low-end mid-single-digit growth (4-5%), Bausch + Lomb outperforming with 6% growth. Daily SiHy up 24%, BioTrue +7%. China Singles' Day results to guide 2026 strategy.
- **Surgical Recovery**: EnVista sales recovery faster than expected, Envy surpassing Q1 2025 levels in September. Implantables up 14% QoQ, premium IOLs +67% QoQ.
- **Capital Allocation**: Focus on deleveraging to achieve investment-grade status, with opportunistic M&A and R&D investments. 2025 generics business showing sequential improvement.
- **Dry Eye Market**: Miebo TRx +110% YoY, Xiidra +8%. Combination therapies (e.g., lifitegrast + Miebo) expected to expand market. Pipeline includes first-in-class ocular pain med and myopia-slowing contact lenses.

Bausch + Lomb Corporation (BLCO) Q3 2025 Earnings Call Transcript

- **Revenue Resilience**: Q2 growth of 3% YoY, driven by Vision Care (+6%) and Surgical (+15% ex-recall). Dry eye portfolio up 16% on strong Blink and Artelac performance.
- **enVista Recovery**: 200,000 lenses shipped post-recall; full momentum expected by Q1 2026 with Q3/Q4 ramp-up.
- **Dry Eye Dominance**: Miebo prescriptions +111% YoY, Xiidra TRx +12% YoY. New preservative-free LUMIFY variant launched in May.
- **Financial Strength**: Raised 2025 revenue guidance to $5.05-5.15B (5-7% growth), EBITDA $860-910M. Tariff impact fully offset in guidance.
- **Pipeline Catalysts**: 2025 Investor Day to detail Phase 3 candidates in dry eye, glaucoma, and pain. Biomimetic contact lens trial set for Q4.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 revenue of $1.278 billion (+3% YoY), driven by strong performance in Vision Care (6% growth) and Surgical segments (+1% excluding recall impact). Dry eye portfolio grew 16% on a constant currency basis.
- **enVista Recovery**: Resupply efforts underway, with 200,000 lenses shipped post-recall. Implantable lenses expected to ramp up in Q3 and Q4, targeting full momentum by Q1 2026.
- **Dry Eye Leadership**: Blink and Artelac grew 13% and 34%, respectively. Miebo prescriptions up 111% YoY, Xiidra TRx +12% YoY. New preservative-free LUMIFY variant launched in May.
- **Contact Lens Innovation**: Daily SiHy franchise up 36%, Ultra monthly +8%, and Biotrue +2%. Expansion of premium IOLs (e.g., LuxLife) and planned enVista MV launch in Europe.
- **Pipeline Momentum**: 2025 Investor Day to showcase Phase 3 candidates in dry eye, glaucoma, and pain. Biomimetic contact lens clinical trial set for Q4.

**【CFO Financial Commentary】**
- **Q2 Financials**: Adjusted EBITDA $192M (excluding $37M recall and generics impact). Gross margin 60.6% (-130bps YoY due to recall and mix). R&D investment $96M (+12% YoY).
- **Guidance Update**: Full-year revenue raised to $5.05-5.15B (5-7% growth), EBITDA $860-910M. 2025 adjusted tax rate ~15%, interest expense $375M, CapEx $280M.
- **Tariff Mitigation**: 40bps headwind absorbed in guidance. Team actions to offset $120M+ impact from U.S. trade policies.
- **Generics Turnaround**: New leadership sees sequential improvement in Q2; expects stabilization in H2 2025.

**【Q&A Highlights】**
- **CEO Contract Extension**: Renewed for long-term due to confidence in pipeline (e.g., dry eye, IOLs) and team execution despite challenges (recall, tariffs).
- **Dry Eye Competition**: Miebo's evaporative dry eye focus and tolerability differentiate it from competitors. Xiidra's 12% TRx growth driven by education and coverage expansion.
- **Contact Lens Resilience**: Despite industry destocking fears, BLCO's U.S. (+11%), LatAm (+25%), and China (+7%) growth outperformed market.
- **Tariff Strategy**: Proactive supply chain diversification (e.g., U.S.-made generics) offsets 40bps impact; no material impact expected beyond 2025.
- **Pipeline Ambition**: 2025 Investor Day to detail Phase 3+ candidates in dry eye (combination therapy), glaucoma (neuroprotective), and pain (new chemical entity).

Bausch + Lomb (BLCO)-30 Jul 25-2025 Q2 Earnings call transcript

- **Q1 Strong Performance**: 5% constant currency revenue growth across all segments, driven by 42% Daily SiHy growth and 98% MIEBO prescriptions YoY.
- **EnVista Recall Recovery**: Full production resumed in April; Q3/Q4 recovery expected, with $55M one-time 2025 impact.
- **Tariff Mitigation**: 120bp EBITDA margin headwind offset by inventory, manufacturing shifts, and pricing adjustments.
- **Pipeline Momentum**: Biomimetic lens Phase 2 and glaucoma drug Phase 2 studies to begin H2 2025, targeting functional vision improvements.

**【CEO Summary Section】**
- Q1 2025 revenue grew 5% in constant currency, driven by strong performance in Vision Care (5%), Surgical (11%), and Pharmaceuticals (1%).
- Voluntary recall of enVista IOLs in late March led to a $55M one-time revenue impact and $65M EBITDA headwind for 2025. Production resumed in April, with full market re-entry expected by Q4.
- Daily SiHy contact lenses grew 42% Q1, Blink dry eye franchise expanded 84%, and MIEBO prescriptions surged 98% YoY.
- 2025 guidance raised to $5B-$5.1B revenue, absorbing recall impact but benefiting from favorable currency trends.

**【CFO Financial Commentary】**
- Q1 2025 adjusted EBITDA was $126M, including $16M recall-related inventory write-off and $14M margin pressure from U.S. Generics decline.
- Full-year 2025 EBITDA guidance updated to $850M-$900M, incorporating recall headwinds and $120M tariff impact on EBITDA margin.
- Tariff mitigation strategies include inventory stocking, in-house manufacturing shifts (e.g., Daily SiHy in Rochester and Ireland), and pricing adjustments.
- Adjusted tax rate lowered to 15% due to recall-related deductions.

**【Q&A Key Highlights】**
- **EnVista Recovery**: Surgeons plan to resume enVista implants within weeks of supply restoration; Q3/Q4 recovery expected, with full confidence in long-term growth.
- **Tariff Mitigation**: Immediate actions (inventory management, free trade zones) and long-term strategies (manufacturing shifts) aim to offset 120bp EBITDA margin impact.
- **Consumer Resilience**: U.S. and China contact lens demand remained strong (6% growth in China), despite macroeconomic concerns.
- **Pipeline Progress**: Biomimetic contact lens Phase 2 study to begin H2 2025; glaucoma drug Phase 2 confirmatory study expected in Q4 2025.

Bausch + Lomb Corporation (BLCO) Q1 2025 Earnings Call Transcript

- **Record Growth**: 17% constant currency revenue growth in 2024, driven by double-digit gains across all segments.
- **Pipeline Breakthroughs**: 15 new product launches in 2024, including Miebo and Daily SiHy lenses, with biomimetic contact lenses in clinical trials.
- **Profitability Improvement**: 62.6% adjusted gross margin in 2024, up 160bps YoY, with free cash flow turning positive in 2025.
- **Strategic Investments**: $280M CapEx for growth, $93M R&D spend, and Elios MIGS device FDA approval targeting 2025.
- **Dry Eye Dominance**: Miebo exceeded $172M in 2024, Xiidra grew 14% YoY, with Blink NutriTears sales up 4x post-ad launch.


**【CEO Summary Section】**
- **Revenue Growth**: Achieved 17% constant currency revenue growth for the full year, driven by double-digit growth across all segments (Vision Care +10%, Surgical +11%, Pharma +45%).
- **Innovation Momentum**: Introduced 15 new products in 2024, including Miebo (dry eye drug) and Daily SiHy contact lenses. Pipeline includes biomimetic contact lenses, myopia control solutions, and AREDS3 supplements.
- **Execution Excellence**: Organic revenue CAGR of 10% over two years, with premium IOL revenue up 35% in 2024. Daily SiHy lenses grew 75% Q4, outpacing market growth.
- **Technology Integration**: Deployed AI in manufacturing and salesforce tools, reducing backorders and improving rep efficiency. Digital platforms like Opal and Glimpse drive direct-to-consumer engagement.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Total revenue $1.28B (+11% YoY), adjusted EBITDA $259M (+14% YoY). Full year revenue $4.79B (+17% YoY), adjusted EBITDA $878M (+20% YoY).
- **Gross Margin Expansion**: Adjusted gross margin 62.6% for the year, up 160bps YoY, driven by higher-margin product mix.
- **2025 Guidance**: Revenue $4.95B-$5.05B (+5.5%-7.5% YoY), adjusted EBITDA $900M-$950M. Free cash flow expected to turn positive after $263M generated in 2024.
- **Key Investments**: $93M Q4 R&D spend (7% of revenue), $25M IPR&D impact from Inflation Reduction Act, and $280M CapEx for growth initiatives.

**【Q&A Highlights】**
- **Dry Eye Portfolio**: Miebo delivered $172M in 2024, exceeding guidance. Xiidra grew 14% YoY, with TRx momentum expected to continue in 2025. Direct-to-consumer campaigns for Blink NutriTears and LUMIFY preservative-free eye drops drove 4x sales growth.
- **Contact Lens Growth**: Daily SiHy lenses grew 75% Q4, outperforming market. China direct-to-consumer investments drove 18% full year growth. Biomimetic lens clinical trials show promising results, targeting 2027 launch.
- **Surgical Innovation**: Envy IOLs implanted in 10,000+ patients, with Elios MIGS device expected FDA approval in 2025. Adjustable IOLs in early development pipeline.
- **Financial Leverage**: 2024 P&L leverage of 50bps, with 60bps margin expansion expected in 2025. Long-term focus on sustainable margin growth through premium product expansion.


Actual	0.24	0.29	0.31	0.23	0.1	0.18	0.22	0.24	0.07	0.13	0.17	0.25	-0.07	0.07	0.18	0.32
Forecast	0.234	0.1964	0.2388	0.223	0.1354	0.1457	0.1881	0.1692	0.0703	0.1285	0.1573	0.2298	0.021	0.0623	0.1595	0.3626	0.0502
Surprise	+2.56%	+47.66%	+29.82%	+3.14%	-26.14%	+23.54%	+16.96%	+41.84%	-0.43%	+1.17%	+8.07%	+8.79%	-433.33%	+12.36%	+12.85%	-11.75%	0.00%

BLCO

BLCO fundamentals

BLCO Q1 2026 Earnings Preview

Earnings Call

You can ask Aime

BLCO

BLCO fundamentals

BLCO Q1 2026 Earnings Preview

Earnings Call

BLCO Earnings Call Summary for Q1/2026Upcoming Apr 1, 2026

BLCO Earnings Call Summary for Q4/20259:00 AM on Feb 18, 2026

BLCO Earnings Call Summary for Q3/20258:00 AM on Oct 29, 2025

BLCO Earnings Call Summary for Q2/20258:00 AM on Jul 30, 2025

BLCO Earnings Call Summary for Q1/20258:00 AM on Apr 30, 2025

You can ask Aime